{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:54:51Z","timestamp":1794682491436,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12325-020-01555-z","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T09:04:52Z","timestamp":1605603892000},"page":"137-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Medical Therapy for Fibroids: What Next for Ulipristal Acetate?"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-6523","authenticated-orcid":false,"given":"Emmanuel","family":"Ekanem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"1555_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ogrm.2014.05.007","volume":"24","author":"VS Talaulikar","year":"2014","unstructured":"Talaulikar VS. Uterine fibroids and ulipristal. Obstet Gynaecol Reprod Med. 2014;24:254\u20135.","journal-title":"Obstet Gynaecol Reprod Med"},{"key":"1555_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.rbmo.2018.04.040","volume":"37","author":"J Donnez","year":"2018","unstructured":"Donnez J, Courtoy GE, Donnez O, et al. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online. 2018;37:216\u201323.","journal-title":"Reprod Biomed Online"},{"key":"1555_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/IJWH.S51083","volume":"6","author":"AT Khan","year":"2014","unstructured":"Khan AT, Shehmar M, Gupta JKU. Uterine fibroids: current perspectives. Int J Womens Health. 2014;6:95\u2013114.","journal-title":"Int J Womens Health"},{"key":"1555_CR4","first-page":"285","volume":"8","author":"N Biglia","year":"2014","unstructured":"Biglia N, Carinelli S, Maiorana A, et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Dev Ther. 2014;8:285\u201392.","journal-title":"Drug Des Dev Ther"},{"key":"1555_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/09513590.2015.1106471","volume":"32","author":"T Kalampokas","year":"2016","unstructured":"Kalampokas T, Kamath M, Boutas I, et al. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32:91\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"1555_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.bpobgyn.2008.01.009","volume":"22","author":"A Khaund","year":"2008","unstructured":"Khaund A, Lumsden MA. Impact of fibroids on reproductive function. Best Pract Res Clin Obstet Gynaecol. 2008;22:749\u201360.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1555_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bpobgyn.2017.09.007","volume":"46","author":"V Sinai","year":"2018","unstructured":"Sinai V. Medical therapy for fibroids: an overview. Best Pract Res Clin Obstet Gynaecol. 2018;46:48\u201356.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1555_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bpobgyn.2017.10.008","volume":"46","author":"J Donnez","year":"2018","unstructured":"Donnez J, Donnez O, Dolmans MM. The current place of medical therapy in uterine fibroid management. Best Pract Res Clin Obstet Gynaecol. 2018;46:57\u201365.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1555_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/TCRM.S147318","volume":"15","author":"M Farris","year":"2019","unstructured":"Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: an update on current and emerging treatment options. Ther Clin Risk Manag. 2019;15:157\u201378.","journal-title":"Ther Clin Risk Manag"},{"key":"1555_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/IJWH.S15710","volume":"3","author":"N Duhan","year":"2011","unstructured":"Duhan N. Current and emerging treatments for uterine myoma\u2014an update. Int J Womens Health. 2011;3:231\u201342.","journal-title":"Int J Womens Health"},{"key":"1555_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jogc.2015.11.005","volume":"38","author":"K Arendas","year":"2016","unstructured":"Arendas K, Leyland NA. Use of ulipristal acetate for the management of fibroid-related acute abnormal uterine bleeding. J Obstet Gynaecol Canada. 2016;38:80\u20133.","journal-title":"J Obstet Gynaecol Canada"},{"key":"1555_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejogrb.2017.06.047","volume":"216","author":"F Faustino","year":"2017","unstructured":"Faustino F, Martinho M, Reis J, et al. Update on medical treatment of uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2017;216:61\u20138.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1555_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejogrb.2012.07.023","volume":"165","author":"VS Talaulikar","year":"2012","unstructured":"Talaulikar VS, Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2012a;165:135\u201340.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1555_CR14","unstructured":"National Institute for Health Care and Excellence (2018) Heavy menstrual bleeding: assessment and management, https:\/\/www.nice.org.uk\/guidance\/ng88\/resources\/heavy-menstrual-bleeding-assessment-and-management-pdf-1837701412549. Accessed 1 Oct 2020."},{"key":"1555_CR15","first-page":"565","volume":"10","author":"VS Talaulikar","year":"2014","unstructured":"Talaulikar VS, Manyonda I. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids. Women\u2019s Health. 2014;10:565\u201370.","journal-title":"Women\u2019s Health"},{"key":"1555_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12325-012-0042-8","volume":"29","author":"VS Talaulikar","year":"2012","unstructured":"Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther. 2012b;29:655\u201363.","journal-title":"Adv Ther"},{"key":"1555_CR17","first-page":"1","volume":"2018","author":"T Rabe","year":"2018","unstructured":"Rabe T, Saenger N, Ebert AD, et al. Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate. Biomed Res Int. 2018;2018:1\u201312.","journal-title":"Biomed Res Int"},{"key":"1555_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409\u201320.","journal-title":"N Engl J Med"},{"key":"1555_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa1103180","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tomaszewski J, V\u00e1zquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421\u201332.","journal-title":"N Engl J Med"},{"key":"1555_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.02.008","author":"J Donnez","year":"2014","unstructured":"Donnez J, V\u00e1zquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.02.008 (Epub ahead of print 2014).","journal-title":"Fertil Steril"},{"key":"1555_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","volume":"103","author":"J Donnez","year":"2015","unstructured":"Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519\u201327.","journal-title":"Fertil Steril"},{"key":"1555_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09513590.2019.1640202","volume":"36","author":"A Biscione","year":"2020","unstructured":"Biscione A, Barra V, Bellone E, Severi FMLS. Ulipristal acetate on quality of life and sexual function of women with uterine fibromatosis. Gynecol Endocrinol. 2020;36:87\u201392.","journal-title":"Gynecol Endocrinol"},{"key":"1555_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jmig.2015.12.002","volume":"23","author":"S Ferrero","year":"2016","unstructured":"Ferrero S, Racca A, Tafi E, Alessandri F, Venturini PLLRMU. Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study. J Minim Invasive Gynecol. 2016;23:390\u20135.","journal-title":"J Minim Invasive Gynecol"},{"key":"1555_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/09513590.2019.1680626","volume":"36","author":"S Del Forno","year":"2020","unstructured":"Del Forno S, Degli Esposti E, Salucci P, Leonardi D, Iodice R, Arena A, Raimondo D, Paradisi RSR. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience. Gynecol Endocrinol. 2020;36:445\u20137.","journal-title":"Gynecol Endocrinol"},{"key":"1555_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/01443615.2017.1405926","volume":"38","author":"SI Natalie Woodhead","year":"2018","unstructured":"Natalie Woodhead SI, Rachel Pounds PP. Ulipristal acetate for uterine fibroids: 2 years of real-world experience in a UK hospital. J Obstet Gynaecol (Lahore). 2018;38:813\u20137.","journal-title":"J Obstet Gynaecol (Lahore)"},{"key":"1555_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jmig.2019.04.026","volume":"27","author":"C Frasc\u00e0","year":"2020","unstructured":"Frasc\u00e0 C, Arena A, Degli Esposti E, Raimondo D, Del Forno S, Moro E, Zanello M, Mabrouk MSR. First impressions can be deceiving: surgical outcomes of laparoscopic myomectomy in patients pretreated with ulipristal acetate. J Minim Invasive Gynecol. 2020;27:633\u20138.","journal-title":"J Minim Invasive Gynecol"},{"key":"1555_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmig.2017.02.025","volume":"24","author":"L Luketic","year":"2017","unstructured":"Luketic L, Shirreff L, Kives S, et al. Does ulipristal acetate affect surgical experience at laparoscopic myomectomy? J Minim Invasive Gynecol. 2017;24:797\u2013802.","journal-title":"J Minim Invasive Gynecol"},{"key":"1555_CR28","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen M, Suzuki A, Thakkar S, et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21:648\u201353.","journal-title":"Drug Discov Today"},{"key":"1555_CR29","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hep.22272","volume":"47","author":"C Lammert","year":"2008","unstructured":"Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003\u20139.","journal-title":"Hepatology"},{"key":"1555_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.fertnstert.2018.06.044","volume":"110","author":"J Donnez","year":"2018","unstructured":"Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110:593\u20135.","journal-title":"Fertil Steril"},{"key":"1555_CR31","doi-asserted-by":"publisher","DOI":"10.22201\/fq.18708404e.2004.3.66178","volume-title":"Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses","author":"S Branch","year":"2015","unstructured":"Branch S. Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses. Geneva: World Health Organization; 2015. https:\/\/doi.org\/10.22201\/fq.18708404e.2004.3.66178."},{"key":"1555_CR32","doi-asserted-by":"publisher","DOI":"10.22201\/fq.18708404e.2004.3.66178","volume-title":"Esmya (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver function before, during and after treatment","author":"J Raine","year":"2015","unstructured":"Raine J. Esmya (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver function before, during and after treatment. Geneva: World Health Organization; 2015. https:\/\/doi.org\/10.22201\/fq.18708404e.2004.3.66178."},{"key":"1555_CR33","unstructured":"Agency EM. Esmya: new measures to minimise risk of rare but serious liver injury. 2018"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01555-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01555-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:34:46Z","timestamp":1612301686000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01555-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01555-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"10 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}